Galanin (GAL) is a multifunctional neuropeptide widely distributed in the central and peripheral nervous systems, regulating nociception, cognition, mood, and neuroendocrine pathways. Targeting the Galanin system—including its three G-protein coupled receptors, GALR1, GALR2, and GALR3—presents therapeutic opportunities in neuropathic pain, epilepsy, metabolic disorders, and oncology. Developing selective modulators requires high-purity ligands and robust GPCR-expressing cellular models.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Galanin (GAL) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GAL Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GAL Products |
| Gene Delivery | GALR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GALR1 Products |
| Gene Delivery | GALR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GALR2 Products |
| Benchmark Ab | Anti-GAL Recombinant Antibody Recombinant positive control for validation. |
View GAL Products |
| Validator | GAL siRNA Set For knockdown verification. |
View GAL Products |
| Related Target A | GALR1 Primary inhibitory receptor coupled to Gi/o, mediating analgesic and anticonvulsant effects. |
View GALR1 Products |
| Related Target B | GALR2 Excitatory receptor coupled to Gq/11, involved in cell survival and neurite outgrowth. |
View GALR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation & Signaling Assay | Lentivirus premade particles for stable, native-conformation GALR1/2/3 cell line generation. |
| Subfamily Cross-Reactivity Screening | High-purity, sequence-verified GPCR target panels to evaluate receptor-selective binding. |
| Lack of Controls | Sequence-verified biosimilar antibodies included for assay bench-marking. |
| False Positives | Validated siRNA sets included for specific target knockdown verification. |
Live Galanin (GAL) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Galanin (GAL) and Galanin receptor (GALR) therapeutics is intensifying, with major players shifting focus from traditional peptide mimics to non-peptide small molecule agonists/antagonists and selective biologics. As first-generation peptide therapies face blood-brain barrier (BBB) penetration challenges, the next wave of R&D is targeting receptor-selective small molecules and antibody-drug conjugates (ADCs) or neutralizing antibodies for oncological applications where GALRs are dysregulated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Academic Institutes, Biotech | Neuropathic Pain, Epilepsy | Calcium Flux / cAMP Assay (Need GPCR Lentivirus for stable cell lines) |
| Peptide Analogs | Specialty Pharma | Metabolic Diseases, Diabetes | Binding Affinity Assays (Need sequence-verified high-purity GAL protein) |
| Monoclonal Antibodies | Oncology Biotechs | Solid Tumors, Neuroendocrine Tumors | Specificity Screening (Need GALR1/2/3 subfamily selectivity panels) |